AZIZ SHAIBANI to Myositis, Inclusion Body
This is a "connection" page, showing publications AZIZ SHAIBANI has written about Myositis, Inclusion Body.
Connection Strength
0.578
-
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2023 10; 22(10):900-911.
Score: 0.223
-
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT. Neurology. 2021 03 23; 96(12):e1595-e1607.
Score: 0.186
-
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial. Lancet Neurol. 2019 09; 18(9):834-844.
Score: 0.168